SOLTF Quote, Financials, Valuation and Earnings

Healios KK has a net margin of 12.96% compared to Nxera Pharma's net margin of -107.23%. Nxera Pharma's return on equity of -5.58% beat Healios KK's return on equity of -137.21%.

Nxera Pharma has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Nxera Pharma has higher upside potential than Healios KK, analysts believe Nxera Pharma is more attractive than Healios KK.

Nxera Pharma has a beta of 0.337, which suggesting that the stock is 66.345% less volatile than S&P 500. In comparison Healios KK has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Nxera Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nxera Pharma pays -- of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend.

Nxera Pharma quarterly revenues are $62.4M, which are larger than Healios KK quarterly revenues of $3.2M. Nxera Pharma's net income of $8.1M is higher than Healios KK's net income of -$3.4M. Notably, Nxera Pharma's price-to-earnings ratio is -- while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nxera Pharma is 2.79x versus 32.00x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.

PeptiDream has a net margin of 12.96% compared to Nxera Pharma's net margin of -5.57%. Nxera Pharma's return on equity of -5.58% beat PeptiDream's return on equity of 34.66%.

Nxera Pharma has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that Nxera Pharma has higher upside potential than PeptiDream, analysts believe Nxera Pharma is more attractive than PeptiDream.

Nxera Pharma has a beta of 0.337, which suggesting that the stock is 66.345% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.826, suggesting its less volatile than the S&P 500 by 17.389%.

Nxera Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nxera Pharma pays -- of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend.

Nxera Pharma quarterly revenues are $62.4M, which are larger than PeptiDream quarterly revenues of $36.8M. Nxera Pharma's net income of $8.1M is higher than PeptiDream's net income of -$2.1M. Notably, Nxera Pharma's price-to-earnings ratio is -- while PeptiDream's PE ratio is 20.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nxera Pharma is 2.79x versus 7.14x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.

SanBio has a net margin of 12.96% compared to Nxera Pharma's net margin of --. Nxera Pharma's return on equity of -5.58% beat SanBio's return on equity of --.

Nxera Pharma has a consensus price target of --, signalling downside risk potential of --. On the other hand SanBio has an analysts' consensus of -- which suggests that it could fall by --. Given that Nxera Pharma has higher upside potential than SanBio, analysts believe Nxera Pharma is more attractive than SanBio.

Nxera Pharma has a beta of 0.337, which suggesting that the stock is 66.345% less volatile than S&P 500. In comparison SanBio has a beta of -0.336, suggesting its less volatile than the S&P 500 by 133.637%.

Nxera Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SanBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nxera Pharma pays -- of its earnings as a dividend. SanBio pays out -- of its earnings as a dividend.

Nxera Pharma quarterly revenues are $62.4M, which are larger than SanBio quarterly revenues of --. Nxera Pharma's net income of $8.1M is higher than SanBio's net income of -$5.8M. Notably, Nxera Pharma's price-to-earnings ratio is -- while SanBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nxera Pharma is 2.79x versus 78.05x for SanBio. Usually stocks with elevated PS ratios are considered overvalued.

Takeda Pharmaceutical has a net margin of 12.96% compared to Nxera Pharma's net margin of 7.83%. Nxera Pharma's return on equity of -5.58% beat Takeda Pharmaceutical's return on equity of 4.01%.

Nxera Pharma has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical has an analysts' consensus of $16.03 which suggests that it could grow by 20.8%. Given that Takeda Pharmaceutical has higher upside potential than Nxera Pharma, analysts believe Takeda Pharmaceutical is more attractive than Nxera Pharma.

Nxera Pharma has a beta of 0.337, which suggesting that the stock is 66.345% less volatile than S&P 500. In comparison Takeda Pharmaceutical has a beta of 0.498, suggesting its less volatile than the S&P 500 by 50.209%.

Nxera Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Takeda Pharmaceutical offers a yield of 4.7% to investors and pays a quarterly dividend of $0.33 per share. Nxera Pharma pays -- of its earnings as a dividend. Takeda Pharmaceutical pays out 199.34% of its earnings as a dividend.

Nxera Pharma quarterly revenues are $62.4M, which are smaller than Takeda Pharmaceutical quarterly revenues of $7.9B. Nxera Pharma's net income of $8.1M is lower than Takeda Pharmaceutical's net income of $619.7M. Notably, Nxera Pharma's price-to-earnings ratio is -- while Takeda Pharmaceutical's PE ratio is 21.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nxera Pharma is 2.79x versus 1.39x for Takeda Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.